The presence of mosaic TP53 alterations should be considered in patients with sporadic cancers strongly suggestive of a disease-causing TP53 variant, such as childhood ACC, choroid plexus carcinoma, and breast cancer before 31 years of age and in patients with multiple primary tumours belonging to the TP53 core tumour spectrum [14]. This evidence concerns the gene TP53 and neoplasm.